ACE and chronic kidney disease: Clinical studies have shown that MRAs on top of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) further improve proteinuria, have the potential to slow down CKD progression and reduce the number of CV events in CKD patients [12, 18–20].